Latest News

Dow Jones Newswires: Roche’s vision-loss drug Vabysmo gets EU nod

0

Roche Holding AG said Monday that its vision-loss treatment Vabysmo has been approved in the European Union after successful phase-3 study data.

Vabysmo (faricimab) is a treatment for age-related macular degeneration and visual impairment due to diabetic macular edema, two conditions linked to vision loss, the Swiss pharmaceutical company
ROG,
-0.46%

said.

The approval from the European Commission–the EU’s executive arm–comes after four phase-3 studies showing vision gains and anatomical improvements in patients given the drug, Roche said.

The treatment will now be available in the bloc, adding to approvals in the U.S., the U.K. and Japan, Roche said. Submissions to other regulatory bodies continue, the company said.

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

The Fed: Fed to put a ‘firm foot on the brake pedal’ this week

Previous article

Autotrader: What we love and hate about Tesla

Next article

You may also like

Comments

Leave a reply

Your email address will not be published.

More in Latest News